acalabrutinib
Showing 1 - 25 of 86
Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- Obinutuzumab
- (no location specified)
Jul 10, 2023
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Nemtabrutinib
- +2 more
- (no location specified)
Nov 22, 2023
Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)
Active, not recruiting
- Post-transplant Lymphoproliferative Disorder
- Rituximab
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Jan 16, 2023
Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Oct 31, 2022
Acalabrutinib in Chronic Lymphocytic Leukaemia in United Kingdom
Recruiting
- Chronic Lymphocytic Leukemia, CLL
- Acalabrutinib
-
Aylesbury, United Kingdom
- +7 more
Jan 12, 2023
Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)
Not yet recruiting
- Mantle Cell Lymphoma (MCL)
- Acalabrutinib
- +2 more
-
Duarte, California
- +11 more
Jul 17, 2023
Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Not yet recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- Venetoclax
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 10, 2023
Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +4 more
-
Scottsdale, Arizona
- +2 more
Jan 5, 2023
Chronic Lymphocytic Leukemia (CLL) Trial in United States (Venetoclax, Obinutuzumab, Acalabrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Venetoclax
- +2 more
-
Stamford, Connecticut
- +4 more
Dec 2, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 2, 2022
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
- Acalabrutinib
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Acalabrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
May 13, 2022
Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- +8 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 12, 2023
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)
Not yet recruiting
- Lymphoma
- Mantle Cell Lymphoma
- Acalabrutinib
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
Waldenstrom Macroglobulinemia Trial in Canada (Acalabrutinib, Bendamustine, Rituximab)
Recruiting
- Waldenstrom Macroglobulinemia
- Acalabrutinib
- +2 more
-
Calgary, Alberta, Canada
- +8 more
Nov 9, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Chronic Lymphocytic Leukemia, CLL/SLL Trial in New York (Acalabrutinib)
Withdrawn
- Chronic Lymphocytic Leukemia
- CLL/SLL
- Acalabrutinib
-
New York, New YorkWeill Cornell Medicine
Mar 25, 2022
CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)
Recruiting
- Central Nervous System Lymphoma
- Acalabrutinib
- Isavuconazole
-
Chapel Hill, North Carolina
- +1 more
Mar 24, 2022